Stacie Dusetzina

August 10, 2023

New leaders named to Vanderbilt-Ingram research programs

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center’s research programs.

By Tom Wilemon
Stacie Dusetzina, PhD, right, on the South Lawn of the White House with colleagues Rachel Sachs, JD, MPH, of Washington University St. Louis, left, and Michell Mello, PhD, of Stanford.
November 3, 2022

Researcher’s decade of analyzing the price of drugs leads to big reforms

Vanderbilt’s Stacie Dusetzina, PhD, and several colleagues were able to reflect recently on the South Lawn of the White House about how their contributions through research and data informed the provisions in the Inflation Reduction Act that will save older Americans on Medicare tens of thousands of dollars in out-of-pocket costs each year.

By Jake Lowary
May 10, 2022

New study illustrates how much it would cost for cancer drugs covered under Medicare Part D

A new study by Vanderbilt researchers highlights how some older Americans diagnosed with cancer can face unlimited out-of-pocket spending for prescription drugs under the current structure of the Medicare Part D benefit.

By Jake Lowary
April 4, 2022

Medicare beneficiaries without low-income subsidies were less likely to fill important prescriptions, new study finds

Vanderbilt research shows that Medicare Part D beneficiaries who did not receive federal subsidies to lower their out-of-pocket costs were nearly twice as likely as others to not fill prescriptions for serious health conditions like cancer or hepatitis C treatment.

By Jake Lowary
June 2, 2021

Dusetzina appointed to federal Medicare Payment Advisory Commission

Stacie Dusetzina, PhD, associate professor of Health Policy and Ingram Associate Professor of Cancer Research at Vanderbilt University School of Medicine, has been appointed to a three-year term on the Medicare Payment Advisory Commission (MedPAC).

By Jake Lowary
December 3, 2020

Panel discusses current health policy landscape

The difficulty of policymaking with a divided government and electorate was the underlying theme of the Research into Policy and Practice webinar sponsored by the Department of Health Policy at Vanderbilt University Medical Center as panelists and attendees gathered virtually to take measure of the post-election American landscape, over which hangs the pall of a surging pandemic.

By Jill Clendening
August 6, 2020

Study finds Medicare Part D favors generic drugs over brand-name counterparts

Contrary to previous media reports, a new study led by Vanderbilt University Medical Center researchers finds that Medicare Part D prescription drug insurance plans largely favor generic drugs over brand-name counterparts.
By Jake Lowary
May 7, 2020

Rheumatoid arthritis patients on Medicare seeing increased out-of-pocket costs for specialty medications

After a sharp drop in out-of-pocket costs between 2010 and 2011, Medicare patients who use specialty biologic medications for rheumatoid arthritis have seen higher out-of-pocket spending for those same drugs because of gradual price increases, a new study finds.
By Jake Lowary
July 1, 2019

Study shows some generics can cost Medicare recipients more than brand-name drugs

Medicare Part D enrollees may pay more out of pocket for high-priced specialty generic drugs than their brand-name counterparts, according to new research by health policy experts at Vanderbilt University Medical Center and the University of North Carolina at Chapel Hill.
By Jake Lowary
August 9, 2018

Study to explore how rising medication costs impact elderly

As both drug prices and out-of-pocket expense for prescription medications continue to climb, a team of Health Policy experts at Vanderbilt University School of Medicine (VUSM) have received a grant to determine if these factors are causing older Americans enrolled in Medicare Part D for medication coverage to delay or never fill their prescriptions.
By Jill Clendening
May 9, 2018

Study finds generic options offer limited savings for expensive drugs

Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released this week.
By Craig Boerner